The Filings Report

Gilead Sciences Inc

GILDNasdaqCIK 882095Healthcare / Biotechnologyfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$7.8B
+10.2% on Q2 FY2025
Net income
−$10.5B
−635.5% on Q2 FY2025
Free cash flow
$3.4B
+376.8% on Q2 FY2025
Diluted EPS
$-8.45
−641.7% on Q2 FY2025
Revenue, TTM
$30.5B
trailing four quarters
Net margin, TTM
-10.6%
net income −$3.2B
Free cash flow, TTM
$12.9B
$13.6B less $609M capex
Cash and equivalents
—
long-term debt $23.8B, Jun 30, 2026
Shares, 12-month change
−0.1%
1.24B shares, Jun 30, 2026
Buybacks, TTM
$1.4B
0.7% of market value
Dividends, TTM
$4.1B
1.9% of market value
Market value
$211.6B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 6, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Gilead Sciences Inc reported revenue of $7.8B, +10.2% on Q2 FY2025, and net loss of $10.5B (−635.5%). Operating margin was −133.2%. Free cash flow, operating cash flow less capital expenditures, was $3.4B ($3.6B less $140M). Diluted earnings per share were $-8.45.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 6, 2026.

Revenue and net incomeRevenueNet income
−$15B−$10B−$5B$0$5B$10BQ3'22, Revenue: $7.0BQ3'22, Net income: $1.8BQ3'22Q4'22, Revenue: $7.4BQ4'22, Net income: $1.6BQ4'22Q1'23, Revenue: $6.4BQ1'23, Net income: $1.0BQ1'23Q2'23, Revenue: $6.6BQ2'23, Net income: $1.0BQ2'23Q3'23, Revenue: $7.1BQ3'23, Net income: $2.2BQ3'23Q4'23, Revenue: $7.1BQ4'23, Net income: $1.4BQ4'23Q1'24, Revenue: $6.7BQ1'24, Net income: −$4.2BQ1'24Q2'24, Revenue: $7.0BQ2'24, Net income: $1.6BQ2'24Q3'24, Revenue: $7.5BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $7.6BQ4'24, Net income: $1.8BQ4'24Q1'25, Revenue: $6.7BQ1'25, Net income: $1.3BQ1'25Q2'25, Revenue: $7.1BQ2'25, Net income: $2.0BQ2'25Q3'25, Revenue: $7.8BQ3'25, Net income: $3.1BQ3'25Q4'25, Revenue: $7.9BQ4'25, Net income: $2.2BQ4'25Q1'26, Revenue: $7.0BQ1'26, Net income: $2.0BQ1'26Q2'26, Revenue: $7.8BQ2'26, Net income: −$10.5BQ2'26−$15B−$10B−$5B$0$5B$10BQ3'22, Revenue: $7.0BQ3'22, Net income: $1.8BQ4'22, Revenue: $7.4BQ4'22, Net income: $1.6BQ4'22Q1'23, Revenue: $6.4BQ1'23, Net income: $1.0BQ2'23, Revenue: $6.6BQ2'23, Net income: $1.0BQ2'23Q3'23, Revenue: $7.1BQ3'23, Net income: $2.2BQ4'23, Revenue: $7.1BQ4'23, Net income: $1.4BQ4'23Q1'24, Revenue: $6.7BQ1'24, Net income: −$4.2BQ2'24, Revenue: $7.0BQ2'24, Net income: $1.6BQ2'24Q3'24, Revenue: $7.5BQ3'24, Net income: $1.3BQ4'24, Revenue: $7.6BQ4'24, Net income: $1.8BQ4'24Q1'25, Revenue: $6.7BQ1'25, Net income: $1.3BQ2'25, Revenue: $7.1BQ2'25, Net income: $2.0BQ2'25Q3'25, Revenue: $7.8BQ3'25, Net income: $3.1BQ4'25, Revenue: $7.9BQ4'25, Net income: $2.2BQ4'25Q1'26, Revenue: $7.0BQ1'26, Net income: $2.0BQ2'26, Revenue: $7.8BQ2'26, Net income: −$10.5BQ2'26

Net income losses drawn in red.

Free cash flow
$0$2B$4B$6BQ3'22, Free cash flow: $2.7BQ3'22Q4'22, Free cash flow: $2.4BQ4'22Q1'23, Free cash flow: $1.6BQ1'23Q2'23, Free cash flow: $2.2BQ2'23Q3'23, Free cash flow: $1.6BQ3'23Q4'23, Free cash flow: $2.0BQ4'23Q1'24, Free cash flow: $2.1BQ1'24Q2'24, Free cash flow: $1.2BQ2'24Q3'24, Free cash flow: $4.2BQ3'24Q4'24, Free cash flow: $2.8BQ4'24Q1'25, Free cash flow: $1.7BQ1'25Q2'25, Free cash flow: $720MQ2'25Q3'25, Free cash flow: $4.0BQ3'25Q4'25, Free cash flow: $3.1BQ4'25Q1'26, Free cash flow: $2.4BQ1'26Q2'26, Free cash flow: $3.4BQ2'26$0$2B$4B$6BQ3'22, Free cash flow: $2.7BQ4'22, Free cash flow: $2.4BQ4'22Q1'23, Free cash flow: $1.6BQ2'23, Free cash flow: $2.2BQ2'23Q3'23, Free cash flow: $1.6BQ4'23, Free cash flow: $2.0BQ4'23Q1'24, Free cash flow: $2.1BQ2'24, Free cash flow: $1.2BQ2'24Q3'24, Free cash flow: $4.2BQ4'24, Free cash flow: $2.8BQ4'24Q1'25, Free cash flow: $1.7BQ2'25, Free cash flow: $720MQ2'25Q3'25, Free cash flow: $4.0BQ4'25, Free cash flow: $3.1BQ4'25Q1'26, Free cash flow: $2.4BQ2'26, Free cash flow: $3.4BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$10B$20B$30BQ3'22, Long-term debt: $23.0BQ3'22Q4'22, Cash and equivalents: $5.4BQ4'22, Long-term debt: $23.0BQ4'22Q1'23, Long-term debt: $23.0BQ1'23Q2'23, Long-term debt: $21.2BQ2'23Q3'23, Long-term debt: $23.2BQ3'23Q4'23, Long-term debt: $23.2BQ4'23Q1'24, Long-term debt: $21.5BQ1'24Q2'24, Long-term debt: $21.5BQ2'24Q3'24, Long-term debt: $21.4BQ3'24Q4'24, Long-term debt: $24.9BQ4'24Q1'25, Long-term debt: $22.1BQ1'25Q2'25, Long-term debt: $22.1BQ2'25Q3'25, Long-term debt: $22.1BQ3'25Q4'25, Long-term debt: $22.1BQ4'25Q1'26, Long-term debt: $20.9BQ1'26Q2'26, Long-term debt: $23.8BQ2'26$0$10B$20B$30BQ3'22, Long-term debt: $23.0BQ4'22, Cash and equivalents: $5.4BQ4'22, Long-term debt: $23.0BQ4'22Q1'23, Long-term debt: $23.0BQ2'23, Long-term debt: $21.2BQ2'23Q3'23, Long-term debt: $23.2BQ4'23, Long-term debt: $23.2BQ4'23Q1'24, Long-term debt: $21.5BQ2'24, Long-term debt: $21.5BQ2'24Q3'24, Long-term debt: $21.4BQ4'24, Long-term debt: $24.9BQ4'24Q1'25, Long-term debt: $22.1BQ2'25, Long-term debt: $22.1BQ2'25Q3'25, Long-term debt: $22.1BQ4'25, Long-term debt: $22.1BQ4'25Q1'26, Long-term debt: $20.9BQ2'26, Long-term debt: $23.8BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Gilead Sciences Inc income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue7,8036,9607,9257,7697,0826,6677,5697,545+10.2%
Cost of revenue1,5791,4451,6241,5691,5011,5401,5811,574+5.2%
Gross profit—————————
Research and development—————————
Selling, general and administrative1,9211,4511,7941,3571,3651,2581,9071,433+40.7%
Operating income(10,394)2,5861,9843,3272,4742,2372,452888−520.1%
Other income (expense)387235349569208(328)(35)306+86.1%
Pretax income(10,254)2,5802,0783,6412,4291,6492,167956−522.1%
Income tax242559(105)589468334385(297)−48.3%
Net income(10,496)2,0212,1833,0521,9601,3151,7831,253−635.5%
Diluted EPS ($)(8.45)1.61—2.431.561.04—1.00−641.7%
Diluted shares (millions)1,2431,254—1,2541,2551,259—1,254—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Gilead Sciences Inc balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents—————————
Short-term investments015681969—00−100.0%
Total current assets13,94518,64118,34217,87414,71816,90119,17314,779−5.3%
Total assets49,36256,27859,02358,53355,72156,43458,99554,525−11.4%
Total current liabilities11,0209,47611,81312,29811,18912,34412,00411,725−1.5%
Long-term debt23,83220,86122,12922,13522,14022,14624,89621,437+7.6%
Total liabilities—————————
Stockholders’ equity11,82923,51522,70321,54019,67419,16219,33018,475−39.9%
Shares outstanding (millions)1,2401,2421,2411,2411,2411,2441,2451,246—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 6, 2026.

Gilead Sciences Inc cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 7, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 28, 2025Q3 FY2024ended Sep 30, 2024filed Nov 12, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow3,5732,5443,3274,1088271,7572,9754,309+332.0%
Capital expenditures140117205147107104147141+30.8%
Free cash flow (CFO − capex)3,4332,4273,1223,9617201,6532,8284,168+376.8%
Depreciation and amortization—————————
Share repurchases355419230435527730350300−32.6%
Dividends paid1,0291,0409941,0059941,010973983+3.5%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Gilead Sciences Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 5, 2009FY2007ended Dec 31, 2007filed Aug 5, 2009
Revenue29,44328,75427,11627,28127,30524,68922,44922,12726,10730,39032,63924,89011,2029,7028,3857,9497,0115,3364,230
Cost of revenue6,2346,2516,4985,6576,6014,5724,6754,8534,3714,261—————————
Gross profit———————————————————
Research and development——————9,1065,0183,7345,0983,0142,8542,1201,7601,229————
Selling, general and administrative5,7746,0916,0905,6735,2465,1514,3814,0563,8783,3983,4262,9831,6991,4611,2421,044947797706
Operating income10,0221,6627,6057,3309,9184,0714,2878,20014,12417,63322,19315,2654,5244,0103,7903,9623,5292,6792,165
Other income (expense)7986198(581)(639)(1,418)1,8686765234281543(9)(37)67604259110
Pretax income9,7966906,8595,8148,2781,6695,1607,79913,52917,09721,65914,8564,2083,6123,6513,9143,5022,6732,211
Income tax1,2862111,2471,2482,0771,580(204)2,3398,8853,6093,5532,7971,1511,0388621,024876702635
Net income8,5104805,6654,5926,2251235,3865,4554,62813,50118,10812,1013,0752,5922,8042,9012,6361,9791,585
Diluted EPS ($)6.780.384.503.644.930.104.224.173.519.9411.917.351.811.641.771.661.41*1.03*0.82*
Diluted shares (millions)1,2551,2551,2581,2621,2621,2631,2771,3081,3191,3581,5211,6471,6951,5831,5801,7471,868*1,918*1,929*

Balance sheet

Gilead Sciences Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 5, 2009FY2007ended Dec 31, 2007filed Aug 5, 2009
Cash and equivalents———5,4125,3385,99711,63117,9407,5888,22912,85110,0272,1131,8049,8849081,2731,459968
Short-term investments6801,1799731,1821,41112,72112,14917,9223,6661,7561011959161,191384331—
Total current assets18,34219,17316,08514,44314,77215,99630,29635,83631,82319,58824,76217,7146,9976,15613,9195,7084,8134,278—
Total assets59,02358,99562,12563,17167,95268,40761,62763,67570,28356,97751,71634,66422,57921,24017,30311,5939,6996,937—
Total current liabilities11,81312,00411,28011,23711,61011,3979,75910,60511,6359,2189,8905,7616,4074,2382,5152,4651,8721,221—
Long-term debt22,12924,89623,18922,95725,17928,64522,09424,57430,79526,34621,07311,9213,9397,0557,606————
Total liabilities———————————————————
Stockholders’ equity22,70319,33022,83321,24021,06918,20222,52521,38720,44218,88718,53415,42611,3709,3036,7395,8646,3674,273—
Shares outstanding (millions)1,2411,2451,2461,2471,2541,2571,2641,2761,3101,3071,3671,4891,5381,5221,515*1,591*1,807*——

Cash flow statement

Gilead Sciences Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 28, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 24, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Mar 1, 2010FY2008ended Dec 31, 2008filed Aug 5, 2009FY2007ended Dec 31, 2007filed Aug 5, 2009
Operating cash flow10,01910,8288,0069,07211,3848,1689,1448,40011,89817,04721,25012,8183,1053,1953,6392,8343,0802,1431,669
Capital expenditures5635235857285796508259245907487475571903971326223011579
Free cash flow (CFO − capex)9,45610,3057,4218,34410,8057,5188,3197,47611,30816,29920,50312,2612,9152,7983,5072,7722,8502,0281,590
Depreciation and amortization———————————————————
Share repurchases1,9221,1501,0001,3965461,5831,7492,90095411,00110,0025,3495826672,3834,0239981,970488
Dividends paid4,0033,9183,8093,7093,6053,4493,2222,9712,7312,4551,87400——————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$16M
26 sales by 5 insiders; officers and directors $16M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$88M
78 sales by 7 insiders; officers and directors $88M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 15, 2026Dickinson Andrew DChief Financial Officeropen-market sale10b5-13,000$156.22$469K161,096Oct 16, 2026
Oct 15, 2026Mercier JohannaChief Comm & Corp Aff Officeropen-market sale10b5-13,000$156.22$469K113,684Oct 16, 2026
Oct 1, 2026O'Day Daniel PatrickChairman & CEO, Directoropen-market sale10b5-112,000$147.72$2M569,683Oct 2, 2026
Oct 1, 2026O'Day Daniel PatrickChairman & CEO, Directoropen-market sale10b5-13,000$148.63$446K566,683Oct 2, 2026
Sep 22, 2026Burkhart ErinSVP, Controllershipoption exercise2,223——2,223Sep 23, 2026
Sep 22, 2026Burkhart ErinSVP, Controllershiptax withholding768$152.67$117K1,455Sep 23, 2026
Sep 15, 2026Dickinson Andrew DChief Financial Officeropen-market sale10b5-13,000$145.29$436K164,096Sep 16, 2026
Sep 15, 2026Mercier JohannaChief Comm & Corp Aff Officeropen-market sale10b5-11,600$143.69$230K118,084Sep 16, 2026
Sep 15, 2026Mercier JohannaChief Comm & Corp Aff Officeropen-market sale10b5-1800$144.46$116K117,284Sep 16, 2026
Sep 15, 2026Mercier JohannaChief Comm & Corp Aff Officeropen-market sale10b5-1600$145.29$87K116,684Sep 16, 2026
Sep 10, 2026Dickinson Andrew DChief Financial Officeroption exercise2,797——168,443Sep 11, 2026
Sep 10, 2026Dickinson Andrew DChief Financial Officertax withholding1,347$144.81$195K167,096Sep 11, 2026
Sep 10, 2026Berger DietmarChief Medical Officeroption exercise533——19,785Sep 11, 2026
Sep 10, 2026Berger DietmarChief Medical Officertax withholding263$144.81$38K19,522Sep 11, 2026
Sep 10, 2026Mercier JohannaChief Comm & Corp Aff Officeroption exercise2,797——121,031Sep 11, 2026
Sep 10, 2026Mercier JohannaChief Comm & Corp Aff Officertax withholding1,347$144.81$195K119,684Sep 11, 2026
Sep 10, 2026Cain Wettan Keeley MEVP Gen Counsel, Legal & Compoption exercise590——9,044Sep 11, 2026
Sep 10, 2026Cain Wettan Keeley MEVP Gen Counsel, Legal & Comptax withholding285$144.81$41K8,759Sep 11, 2026
Sep 10, 2026O'Day Daniel PatrickChairman & CEO, Directoroption exercise8,780——585,913Sep 11, 2026
Sep 10, 2026O'Day Daniel PatrickChairman & CEO, Directortax withholding4,230$144.81$613K581,683Sep 11, 2026
Sep 1, 2026O'Day Daniel PatrickChairman & CEO, Directoropen-market sale10b5-11,600$147.51$236K590,533Sep 2, 2026
Sep 1, 2026O'Day Daniel PatrickChairman & CEO, Directoropen-market sale10b5-17,992$148.36$1M582,541Sep 2, 2026
Sep 1, 2026O'Day Daniel PatrickChairman & CEO, Directoropen-market sale10b5-15,408$149.38$808K577,133Sep 2, 2026
Aug 26, 2026Welters AnthonyDirectoroption exercise7,718$60.67$468K20,612Aug 27, 2026
Aug 26, 2026Welters AnthonyDirectoropen-market sale10b5-13,118$148.31$462K17,494Aug 27, 2026

Full insider history for Gilead Sciences Inc, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held GILD in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded GILD by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$2M18,0000.00%trimmed −40.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
GILEAD SCIENCES, INC., CIK 882095 on EDGAR
Extract generated
August 27, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: net income FY2011
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/GILD.json